Rankings
▼
Calendar
SUPN
Supernus Pharmaceuticals, Inc.
$3B
Q3 2016 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$57M
Gross Profit
$53M
94.0% margin
Operating Income
$20M
34.9% margin
Net Income
$62M
108.8% margin
EPS (Diluted)
$1.18
QoQ Revenue Growth
+12.7%
Cash Flow
Operating Cash Flow
$28M
Free Cash Flow
$28M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$285M
Total Liabilities
$112M
Stockholders' Equity
$173M
Cash & Equivalents
$54M
← FY 2016
All Quarters
Q4 2016 →
SUPN Q3 2016 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
